10/12/2021 8:04:22 AM
Seagen And Astellas Complete Enrollment In EV-103 Trial Cohort K Combining PADCEV With Pembrolizumab
10/12/2021 8:02:51 AM
Astellas Closes Enrollment In EV-103 Trial Cohort K Combining PADCEV With Pembrolizumab As Urothelial Cancer Treatment
9/28/2021 8:05:43 AM
Seagen Completes Enrollment In Phase 2 MOUNTAINEER Clinical Trial Of TUKYSA In Combination With Trastuzumab
9/27/2021 3:02:52 AM
Astellas Pharma Says Japan's MHLW Approves PADCEV For Advanced Urothelial Cancer
9/20/2021 7:54:30 AM
William Blair Reiterates Seagen Inc (SGEN) At Outperform
9/19/2021 12:01:14 PM
Seagen And Genmab Present Interim Results From InnovaTV 205 Study For Tisotumab Vedotin Combination Therapy
8/9/2021 6:04:00 AM
Seagen And RemeGen Announce Licensing Deal To Develop Disitamab Vedotin
7/29/2021 4:10:26 PM
Seagen Q2 Loss/share $0.47 Vs. Loss $0.12 Year Ago
4/29/2021 4:07:55 PM
Seagen Q1 Loss/share $0.67 Vs. Loss $0.98 Year Ago
4/19/2021 8:02:40 AM
Astellas And Seagen Announce FDA Acceptance Of Two Supplemental Biologics License Applications For PADCEV
3/26/2021 2:04:54 AM
Astellas Pharma And Seagen: MAA For Enfortumab Vedotin Accepted By European Medicines Agency